The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10206 malaria professionals are enjoying the free benefits of MalariaWorld today


The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis

October 15, 2019 - 15:36 -- Open Access
Robert J. Commons, Julie A. Simpson, Ric N. Price, et al.
PLoS Med 16(10): e1002928

Artemisinin-based combination therapy (ACT) is recommended for uncomplicated Plasmodium vivax malaria in areas of emerging chloroquine resistance. We undertook a systematic review and individual patient data meta-analysis to compare the efficacies of dihydroartemisinin-piperaquine (DP) and artemether-lumefantrine (AL) with or without primaquine (PQ) on the risk of recurrent P. vivax.

Medical Condition: 

Clinical illness and outcomes in Nigerian children with late-appearing anaemia after artemisinin-based combination treatments of uncomplicated falciparum malaria

June 8, 2016 - 15:59 -- Open Access
Sowunmi A, Akano K, Ayede A, Ntadom G, Aderoyeje T, Adewoye E, Fatunmbi B
BMC Infectious Diseases 2016, 16:240 (1 June 2016)

This was an open label study with the main objectives of evaluating the clinical features, the risk factors for, the temporal changes in haematocrit and the outcomes of a LAA in malarious children treated with artesunate-amodiaquine (AA), artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHP). 

Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

March 10, 2016 - 14:14 -- Open Access
Gonçalves B, Tiono A, Bousema T, et al.
BMC Medicine 2016, 14 :40 (8 March 2016)

We observed similar gametocyte clearance rates after 0.25 and 0.40 mg/kg primaquine doses. Infectivity to mosquitoes after AL was very low and absent in primaquine arms.

Maximizing antimalarial efficacy and the importance of dosing strategies

May 12, 2015 - 15:57 -- Open Access
James G Beeson, Philippe Boeuf and Freya JI Fowkes
BMC Medicine 2015, 13:110

In the most recent study, an analysis of clinical trials of artesunate-amodiaquine, widely used among children in Africa, revealed a superior efficacy for fixed-dose combination tablets compared to loose non-fixed dose combinations.

Exposure to artemether-lumefantrine (Coartem®) in first trimester pregnancy in an observational study in Zambia

March 9, 2015 - 14:58 -- Open Access
Christine Manyando, Eric M Njunju, Mailis Virtanen, Kamal Hamed, Melba Gomes, Jean-Pierre Van geertruyden
Malaria Journal 2015, 14:77 (14 February 2015)

This report assessed the longitudinal safety outcomes of the pregnant women inadvertently exposed during the first trimester.

Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens

March 3, 2015 - 14:25 -- Open Access
James Kapisi, Victor Bigira, Tamara Clark, Stephen Kinara, Florence Mwangwa, Jane Achan, Moses Kamya, Seyi Soremekun, Grant Dorsey
Malaria Journal 2015, 14:53 (5 February 2015)

 In the setting of chemoprevention, treatment of uncomplicated malaria with AL was safe and efficacious, with moderate protection against recurrent malaria among children assigned monthly DP.

Therapeutic efficacy of artemether-lumefantrine on treatment of uncomplicated Plasmodium falciparum mono-infection in an area of high malaria transmission in Zambia

November 25, 2014 - 17:06 -- Open Access
Busiku Hamainza, Freddie Masaninga, Hawela Moonga, Mulenga Mwenda, Pascalina Chanda-kapata, Victor Chalwe, Emmanuel Chanda, Mulakwa Kamuliwo, Olusegun Ayorinde Babaniyi
Malaria Journal 2014, 13:430 (17 November 2014)

This study assessed the therapeutic efficacy and safety of artemether-lumefantrine (AL)(Coartem(R)) for the treatment of uncomplicated Plasmodium falciparum malaria in two sentinel high malaria transmission districts in the Eastern Province of Zambia in persons aged six months and above, excluding women aged 12 to 18 years.


Therapeutic efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in North-Eastern Tanzania

September 30, 2014 - 19:13 -- Open Access
Shayo A, Mandara CI, Shahada F, Buza J, Lemnge MM, Ishengoma DS
Malaria Journal 2014, 13 :376 (20 September 2014)

This study showed that AL was safe, well-tolerated and efficacious for treatment of uncomplicated falciparum malaria.

A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine in Ghanaian paediatric sickle cell and non-sickle cell disease patients with acute uncomplicated malaria

September 25, 2014 - 12:07 -- Open Access
Adjei GO, Goka BQ, Enweronu-Laryea CC, Rodrigues OP, Renner L, Sulley AM, Alifrangis M, Khalil I, Kurtzhals JA
Malaria Journal 2014, 13 :369 (19 September 2014)

Children with SCD and acute uncomplicated malaria (n = 60) were randomized to treatment with artesunate-amodiaquine (AA), or artemether-lumefantrine (AL). A comparison group of non-SCD children (HbAA genotype; n = 59) with uncomplicated malaria were also randomized to treatment with AA or AL.

In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique

August 19, 2014 - 14:04 -- Open Access
Nhama A, Bassat Q, Macete E, et al.
Malaria Journal 2014, 13 :309 (10 August 2014)

This study confirms that both AL and ASAQ remain highly efficacious and well tolerated for the treatment of uncomplicated malaria in Mozambican children.

Medical Treatment: 


Subscribe to RSS - artemether-lumefantrine